| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Avapritinib (USAN/INN); Ayvakit (TN); Ayvakyt (TN) | ||||||
| Product | AYVAKIT (Blueprint Medicines Corporation) | ||||||
| Formula | C26H27FN10 | ||||||
| Exact mass | 498.2404 | ||||||
| Mol weight | 498.558 | ||||||
| Structure |  | ||||||
| Class | Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor | ||||||
| Remark |
| ||||||
| Efficacy | Antineoplastic, Receptor tyrosine kinase inhibitor | ||||||
| Disease | Gastrotintestinal stromal tumor (PDGFRA mutaion positive) [DS:H01591] | ||||||
| Target | KIT* (CD117) [HSA_VAR:3815v1] [HSA:3815] [KO:K05091] PDGFRA* [HSA_VAR:5156v2] [HSA:5156] [KO:K04363] | ||||||
| Pathway |
| ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EX Other protein kinase inhibitors L01EX18 Avapritinib D11279 Avapritinib (USAN/INN) <US> USP drug classification [BR:br08302] Antineoplastics Molecular Target Inhibitors Avapritinib D11279 Avapritinib (USAN/INN) Drug groups [BR:br08330] Antineoplastic DG01918 Tyrosine kinase inhibitor DG01917 Receptor tyrosine kinase inhibitor D11279 Avapritinib Target-based classification of drugs [BR:br08310] Protein kinases Receptor tyrosine kinases (RTK) PDGFR family PDGFRA* [HSA_VAR:5156v2] D11279 Avapritinib (USAN/INN) <US> KIT* (CD117) [HSA_VAR:3815v1] D11279 Avapritinib (USAN/INN) <US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11279 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D11279 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11279 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D11279 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 37 1 C8x C 21.6300 -13.4400 2 C8y C 21.6300 -12.0400 3 C8x C 22.8200 -11.3400 4 C8x C 24.0800 -12.0400 5 C8y C 24.0800 -13.4400 6 C8x C 22.8200 -14.1400 7 X F 25.2700 -14.1400 8 C1d C 20.4400 -11.3400 9 C8y C 19.2500 -12.0400 10 C8x C 19.2500 -13.4400 11 N5x N 17.9900 -14.1400 12 C8y C 16.8000 -13.4400 13 N5x N 16.8000 -12.0400 14 C8x C 17.9900 -11.3400 15 N1y N 15.6100 -14.1400 16 C1x C 15.6100 -15.5400 17 C1x C 14.3500 -16.2400 18 N1y N 13.1600 -15.5400 19 C1x C 13.1600 -14.1400 20 C1x C 14.3500 -13.4400 21 C8y C 11.9700 -16.2400 22 N5x N 11.9700 -17.6400 23 C8x C 10.7100 -18.3400 24 N5x N 9.5200 -17.6400 25 N4y N 9.5200 -16.2400 26 C8y C 10.7100 -15.5400 27 C8x C 8.4700 -15.3300 28 C8y C 9.0300 -14.0000 29 C8x C 10.4300 -14.1400 30 C8y C 8.3300 -12.8100 31 C8x C 6.9300 -12.6700 32 N5x N 6.6500 -11.2700 33 N4y N 7.8400 -10.5700 34 C8x C 8.8900 -11.4800 35 C1a C 7.9800 -9.1700 36 C1a C 19.4600 -10.3600 37 N1a N 21.4200 -10.3600 BOND 42 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 5 7 1 8 2 8 1 9 8 9 1 10 9 10 2 11 10 11 1 12 11 12 2 13 12 13 1 14 13 14 2 15 9 14 1 16 12 15 1 17 15 16 1 18 16 17 1 19 17 18 1 20 18 19 1 21 19 20 1 22 15 20 1 23 18 21 1 24 21 22 2 25 22 23 1 26 23 24 2 27 24 25 1 28 25 26 1 29 21 26 1 30 25 27 1 31 27 28 2 32 28 29 1 33 26 29 2 34 28 30 1 35 30 31 1 36 31 32 2 37 32 33 1 38 33 34 1 39 30 34 2 40 33 35 1 41 8 36 1 #Down 42 8 37 1 #Up |